Please assess the completion status of the following clinical trial:

Trial Title: Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All Participants~* Women must be surgically sterile (hysterectomy or bilateral oophorectomy or tubal ligation) or postmenopausal as defined by age \>45 years without use of oral contraceptive agents for greater than 1 year and have either:~  * spontaneous amenorrhea greater than 12 months, or~ * spontaneous amenorrhea 6 to 12 months with documented follicle stimulating hormone (FSH) \>25 milli international units/milliliter (mIU/mL) and serum estradiol \<73 picomoles/liter (pmol/L) (20 picograms/milliliter \[pg/mL\])~* Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures~* Have given written informed consent approved by Lilly and the ethical review board governing the site~* Have serum creatinine \<150 micromoles/liter (µmol/L) (\<1.3 milligrams/deciliter \[mg/dl\] in women, \<170 µmol/L \[\<1.5 mg/dL\] in men)~* Have normal hemoglobin result, as determined by the investigator~Healthy Participants~* Overtly healthy men and women as determined by medical history, normal lab results and physical examination.~* Body mass index (BMI) between 19 and 25 kilograms/meter squared (kg/m\^2), inclusive.~* Normal blood pressure and heart rate as determined by the investigator~* Have a normal response to an oral glucose tolerance test (OGTT) (glucose \<7.8 millimoles/liter \[mmol/L\] \[\<140 mg/dL\] at 2 hours after 75 grams (g) oral glucose load)~Participants with type 2 diabetes mellitus (T2DM)~* Participants will have a BMI between 22.0 and 40.0 kg/m\^2~* Have T2DM controlled with diet and exercise alone or metformin for at least 4 weeks prior to admission~* Have a hemoglobin A1c (HbA1c) value at screening (or within 4 weeks prior to screening) of 6.0% to 9.5%~* Diagnosed with T2DM within the past 10 years~* Clinical laboratory test results within normal range or deemed clinically insignificant by the Investigator. Abnormalities of serum glucose, serum lipids, urinary glucose, and urinary protein consistent with T2DM are acceptable.~* Participants who are taking stable-dose prescription medications (for example, antihypertensive agents, aspirin, lipid-lowering agents) for treatment of concurrent medical conditions are permitted to participate providing the medication is not associated with development of torsade de pointes. However, use of beta-blockers and thiazide diuretics are not permitted during this study.~Exclusion Criteria:~All Participants~* Within 30 days of the initial dose of study drug, have received treatment with a drug that has not received regulatory approval for any indication~* Known allergies to Glucagon-Like Peptide 1 (GLP-1) related compounds~* Have previously completed or withdrawn from this study or any other study in the last year investigating glucagon-like peptides or incretin mimetics including exenatide (Byetta®)~* Regular use of known drugs of abuse and/or positive findings on urinary drug screening, other than findings consistent with medication prescribed by the participant's physician(s)~* History or presence of cardiovascular, respiratory, renal, endocrine (except T2DM), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs or of constituting a risk when taking the study medication or interfering with the interpretation of data~* Have a history or presence of gastrointestinal disorder~* Poorly controlled hypertension (systolic greater than 160 millimeters of mercury \[mmHg\], diastolic greater than 95 mmHg) and/or evidence of labile blood pressure including symptomatic postural hypotension. Use of beta-blockers or thiazide diuretics is not permitted during the study~* Have a clinically significant history of cardiac disease or presence of active cardiac disease within 1 year of the screening period~* Evidence of hepatitis C and/or positive hepatitis C antibody~* Evidence of hepatitis B and/or positive hepatitis B surface antigen~* Evidence of human immunodeficiency virus (HIV) and/or positive for HIV antibodies~* Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females) or are unwilling to follow alcohol restrictions (1 unit = 12 ounces \[oz\] or 360 milliliters\[mL\] of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).~* Smoke more than 10 cigarettes or equivalent in nicotine use or nicotine substitutes per day~* Regular use of systemic corticosteroids by oral, intravenous, or intramuscular route, or potent, inhaled, or intranasal steroids known to have a high rate of systemic absorption~* Have a history or presence of significant active neuropsychiatric disease~* Blood donation of more than 500 mL in the last 3 months or any blood donation within the last month~* Any other condition, which in the opinion of the investigator would preclude participation in the study~* An abnormality in the 12-lead electrocardiogram (ECG) that in the opinion of the investigator increases the risk of participating in the study.~* Any clinically significant abnormal hematology, clinical chemistry, or urinary result(s) as determined by the investigator~* Evidence of significant active uncontrolled endocrine or autoimmune abnormalities (for example thyroid disease, or pernicious anemia) as judged by the screening physician~Healthy Participants~* Intended use of over-the-counter or prescription medication 7 and 14 days, respectively, prior to dosing.~Participants with T2DM~* Clinically significant peripheral vascular occlusive disease (PVOD).~* Known severe exudative diabetic retinopathy~* Known significant autonomic neuropathy as evidenced by urinary retention, diabetic diarrhea, or gastroparesis~* Have experienced a ketoacidotic episode (pH less than 7.3) requiring hospitalization in the last 6 months~* Outpatient use of insulin for control of diabetes within the past 2 years~* Use of antidiabetic agents other than metformin in the 4 weeks prior to study entry or use of thiazolidinediones within 12 weeks of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- LY2189265 then Placebo (Type: EXPERIMENTAL): LY2189265 (Dulaglutide) then Placebo: A single 1.5 milligram (mg) subcutaneous (SC) injection of LY2189265 on Day 1 in Period 1, followed by a single SC injection of Placebo on Day 1 in Period 2.~On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram \[g/kg\] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter \[mmol/L\] or 15 g of 50% dextrose for participants with 3-hour glucose \>10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour \[mL/h\] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered.~There was a washout period of at least 28 days between Periods 1 and 2.
- Placebo then LY2189265 (Type: EXPERIMENTAL): Placebo then LY2189265 (Dulaglutide): A single subcutaneous injection of Placebo on Day 1 in Period 1, followed by a single 1.5 milligrams (mg) subcutaneous injection of LY2189265 on Day 1 in Period 2.~On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram \[g/kg\] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter \[mmol/L\] or 15 g of 50% dextrose for participants with 3-hour glucose \>10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour \[mL/h\] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered.~There was a washout period of at least 28 days between Periods 1 and 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).